Imatinib

Drug Profile

Imatinib

Alternative Names: CGP 57148; CGP 57148B; CTI 571; Gleevec; Glivec; Imatinib mesilate; Imatinib mesylate; QTI 571; Ruvise; STI 571

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Chronic myeloid leukaemia; Acute lymphoblastic leukaemia; Dermatofibrosarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Myelodysplastic syndromes; Systemic mastocytosis
  • Phase II Acute myeloid leukaemia; Fibroma; Non-Hodgkin's lymphoma; Prostate cancer
  • Phase I Mesothelioma
  • No development reported Malignant melanoma
  • Discontinued Diffuse scleroderma; Glioblastoma; Non-small cell lung cancer; Polycythaemia vera; Pulmonary arterial hypertension; Sarcoma; Small cell lung cancer; Systemic scleroderma

Most Recent Events

  • 01 Feb 2017 Novartis terminates a phase III trial in Pulmonary Arterial Hypertension in USA, Australia, Belgium, Germany, Italy, Lithuania, Romania, Turkey and United Kingdom due to not achieving the recruitment target because of change in the development program for imatinib in PAH (NCT01392469)
  • 12 Oct 2016 Discontinued - Phase-II for Diffuse scleroderma in Canada (PO)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top